Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85111 | 0.76 | F10 (0.58) | F10 | |
| SCHEMBL85161 | 0.71 | F10 (0.62) | F10 | |
| SCHEMBL85110 | 0.70 | F10 (0.60) | F10 | |
| SCHEMBL77720 | 0.70 | F10 (0.60) | F10 | |
| SCHEMBL76354 | 0.69 | F10 (0.57) | F10CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL8268512 | 0.69 | F10 (0.59) | F10 | |
| SCHEMBL76876 | 0.68 | F10 (0.46) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8314192 | 0.67 | F10 (0.59) | F10CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL76575 | 0.67 | F10 (0.69) | F10CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL76756 | 0.65 | F10 (0.51) | F10CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004087646-A2 | PYRROLIDINO-1,2-DICARBOXY-1-(PHENYLAMIDE)-2-(4-(3-OXO-MORPHOLINO-4-YL)-PHENYLAMIDE) DERIVATIVES AND RELATED COMPOUNDS FOR USE AS INHIBITORS OF COAGULATION FACTOR XA IN THE TREATMENT OF THROMBO-EMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2004-10-14 | — | — | WO | disclosed |